27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The development of more effective disease-modifying treatments for Alzheimer's disease (AD) is compromised by the lack of streamlined measures to detect and monitor the full spectrum of neurodegeneration, including white matter pathology, which begins early. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Evaluate the performance of emerging Alzheimer disease (AD) plasma biomarkers in a specialty memory clinic. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study aimed to investigate the bidirectional causal relationship between celiac disease (CD) and the risk of Alzheimer disease (AD) or frontotemporal dementia (FTD) using Mendelian randomization (MR), in order to clarify prior inconsistent findings. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Eight proteins were differently expressed in carriers with larger WMH volumes (Figure 1). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The IVW analysis indicated that antithrombotic agents (odds ratio [OR] = 2.12, 95% confidence interval [CI] = 1.03-4.34, p = 0.04), HMG CoA reductase inhibitors (OR = 1.36, 95% CI = 1.07-1.72, p = 0.01), and salicylic acid and derivatives (OR = 2.77, 95% CI = 1.44-5.32, p = 0.002) are a strong risk factor for dementia with Lewy bodies (DLB); diuretics (OR = 1.13, 95% CI = 1-1.27, p = 0.047) and calcium channel blockers (OR = 1.16, 95% CI = 1.04-1.29, p = 0.007) might be a risk factor for vascular dementia; thyroid preparations (OR = 1.03, 95% CI = 1.01-1.06, p = 0.01), diuretics (OR = 1.06, 95% CI = 1.02-1.11, p = 0.004), and immunosuppressants (OR = 1.07, 95% CI = 1.01-1.12, p = 0.001), are a risk factor for frontotemporal dementia; HMG CoA reductase inhibitors is a risk factor for dementia in Alzheimer disease (OR = 1.32, 95% CI = 1.05-1.65, p = 0.01). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study examines the accuracy of CTseg segmentation software to diagnose Alzheimer's disease dementia and other dementias using routine CT scans from a New Zealand memory service. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sex was not a predictor of the total scores of MoCA. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global increase in dementia cases, which is predicted to exceed 152 million by 2050, poses substantial challenges to healthcare systems and caregiving structures. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a neurodegenerative disorder characterized by a significant decline in cognitive function. 4 key findings →
Participants: 65 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results indicated good usability for the MoCA Duo. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mean activity from actigraphy did not differ within dyad members. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
• Understudied Native Hawaiian and Pacific Islander populations in Alzheimer's Disease and Related Dementia. • Risk and resiliency factors in Alzheimer's Disease and Related Dementia for American Samoa adults. • Using the Kimberley Indigenous Cognitive Assessment tool to determine ADRD potentially modifiable risk and protective factors. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The mean age of the cohort was 77.4 ± 6.8 years, with 62% males and nearly equal urban–rural distribution. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundDementia is one of the most prevalent conditions among older adults. 3 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The accuracy of α-synuclein-SAA for DLB was 87% (95% confidence interval [CI]: 77% to 98%) in CSF, 85% (95% CI: 75% to 98%) in skin, 58% (95% CI: 47% to 69%) in olfactory mucosa, and 59% (95% CI: 51% to 66%) in urine. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
• AT use was limited and AT type used varied by caregiver living arrangement. • Most used ATs: daily living support and risk prevention; risk response least used. • Daily living support ATs linked to fewer care hours. • Risk prevention ATs tied to longer PT, higher CarerQol-7D, and lower SRB scores. • Daily support and risk response ATs most likely to extend PT by over six months. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Thirty-one articles were included. This conceptual analysis revealed the evolution of in-home respite care service content over time and summarized three key attributes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Respite for individuals caring for family living with dementia is a common way to take personal time away from caregiving. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
While both caregivers participated in physical activity, their case studies reveal opportunities to optimize physical activity interventions to support members of the caregiving dyad: (1) targeting mitochondrial fitness—the ability of mitochondria to maintain energy homeostasis with aging—so participants can mitigate the onset of NCDs, fatigue, and overall health outcomes; (2) promoting the self-care and psychological benefits of physical activity such as improved mood and social connectedness; and (3) improving the accurate perceptions of participants’ health and physical activity with specific measurable markers of physical activity. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Synthesis of the results identified three overarching key principles and seven actionable practices for consideration when designing or delivering dementia education to the rural and remote health and aged care workforce. 2 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Keeping current with the burden and risk factors of Alzheimer disease and other dementias (ADOD) from global to national levels is critical for healthcare planning, prevention strategies, and the allocation of resources. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease and related dementias disproportionately affect minority racial and ethnic communities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia, a complex and debilitating spectrum of neurodegenerative diseases, presents a profound challenge in the quest for effective treatments. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Digital health innovations hold diagnostic and therapeutic promise but may be subject to biases for underrepresented groups. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The early diagnosis of dementia, a progressive condition impairing memory, cognition, and functional ability in older adults, is essential for timely intervention and improved patient outcomes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →